Advertisement
Screener

EMERGENT BIOSOLUTIONS INC. (EBS) Amortization of Intangible Assets

2.8 / 5 stars · 68/120 Roast Me

EMERGENT BIOSOLUTIONS INC. Amortization of Intangible Assets

EMERGENT BIOSOLUTIONS INC. (EBS) reported Amortization of Intangible Assets of $17.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-06

  • EMERGENT BIOSOLUTIONS INC. amortization of intangible assets for the quarter ending 2026-06-30 was $17.20M, a 6.17% increase year-over-year.
  • EMERGENT BIOSOLUTIONS INC. amortization of intangible assets for the quarter ending 2026-03-31 was $16.50M, a 1.23% increase year-over-year.
  • EMERGENT BIOSOLUTIONS INC. amortization of intangible assets for the quarter ending 2025-12-31 was $16.30M, a 0.00% change year-over-year.
  • EMERGENT BIOSOLUTIONS INC. amortization of intangible assets for the quarter ending 2025-09-30 was $16.30M, a 0.00% change year-over-year.
  • EMERGENT BIOSOLUTIONS INC. amortization of intangible assets for fiscal 2025 was $65.10M, a 0.00% change from fiscal 2024.
  • EMERGENT BIOSOLUTIONS INC. amortization of intangible assets for fiscal 2024 was $65.10M, a 0.76% decline from fiscal 2023.
  • EMERGENT BIOSOLUTIONS INC. amortization of intangible assets for fiscal 2023 was $65.60M, a 9.52% increase from fiscal 2022.
  • EMERGENT BIOSOLUTIONS INC. amortization of intangible assets for fiscal 2022 was $59.90M, a 2.39% increase from fiscal 2021.
Period endAmortization of Intangible Assets 3 monthAmortization of Intangible Assets 3 month as first filedAmortization of Intangible Assets 6 monthAmortization of Intangible Assets 6 month as first filedAmortization of Intangible Assets 9 monthAmortization of Intangible Assets 9 month as first filedAmortization of Intangible Assets 12 monthAmortization of Intangible Assets 12 month as first filed
2026-06-30$17.20M
10-Q · filed 2026-08-06
$33.70M
10-Q · filed 2026-08-06
$50.00M
derived: sum of 3 quarters · filed 2026-08-06
$66.30M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$16.50M
10-Q · filed 2026-05-01
$32.80M
derived: sum of 2 quarters · filed 2026-05-01
$49.10M
derived: sum of 3 quarters · filed 2026-05-01
$65.30M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$16.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$32.60M
derived: sum of 2 quarters · filed 2026-02-27
$48.80M
derived: sum of 3 quarters · filed 2026-08-06
$65.10M
10-K · filed 2026-02-27
2025-09-30$16.30M
10-Q · filed 2025-10-30
$32.50M
derived: sum of 2 quarters · filed 2026-08-06
$48.80M
10-Q · filed 2025-10-30
$65.10M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$16.20M
10-Q · filed 2026-08-06
$32.50M
10-Q · filed 2026-08-06
$48.80M
derived: sum of 3 quarters · filed 2026-08-06
$65.10M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$16.30M
10-Q · filed 2026-05-01
$32.60M
derived: sum of 2 quarters · filed 2026-05-01
$48.90M
derived: sum of 3 quarters · filed 2026-05-01
$65.20M
derived: sum of 4 quarters · filed 2026-05-01
2024-12-31$16.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$32.60M
derived: sum of 2 quarters · filed 2026-02-27
$48.90M
derived: sum of 3 quarters · filed 2026-02-27
$65.10M
10-K · filed 2026-02-27
2024-09-30$16.30M
10-Q · filed 2025-10-30
$32.60M
derived: sum of 2 quarters · filed 2025-10-30
$48.80M
10-Q · filed 2025-10-30
$65.00M
derived: sum of 4 quarters · filed 2026-02-27
2024-06-30$16.30M
10-Q · filed 2025-08-07
$32.50M
10-Q · filed 2025-08-07
$48.70M
derived: sum of 3 quarters · filed 2026-02-27
$65.00M
derived: sum of 4 quarters · filed 2026-02-27
2024-03-31$16.20M
10-Q · filed 2025-05-08
$32.40M
derived: sum of 2 quarters · filed 2026-02-27
$48.70M
derived: sum of 3 quarters · filed 2026-02-27
$64.80M
derived: sum of 4 quarters · filed 2026-02-27
2023-12-31$16.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27
$32.50M
derived: sum of 2 quarters · filed 2026-02-27
$48.60M
derived: sum of 3 quarters · filed 2026-02-27
$65.60M
10-K · filed 2026-02-27
2023-09-30$16.30M
10-Q · filed 2024-11-07
$32.40M
derived: sum of 2 quarters · filed 2024-11-07
$49.40M
10-Q · filed 2024-11-07
$67.30M
derived: sum of 4 quarters · filed 2025-03-04
2023-06-30$16.10M
10-Q · filed 2024-08-07
$33.10M
10-Q · filed 2024-08-07
$51.00M
derived: sum of 3 quarters · filed 2025-03-04
$65.00M
derived: sum of 4 quarters · filed 2025-03-04
2023-03-31$17.00M
10-Q · filed 2024-05-02
$34.90M
derived: sum of 2 quarters · filed 2025-03-04
$48.90M
derived: sum of 3 quarters · filed 2025-03-04
$62.90M
derived: sum of 4 quarters · filed 2025-03-04
2022-12-31$17.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04
$31.90M
derived: sum of 2 quarters · filed 2025-03-04
$45.90M
derived: sum of 3 quarters · filed 2025-03-04
$59.90M
10-K · filed 2025-03-04
2022-09-30$14.00M
10-Q · filed 2023-12-11
$28.00M
derived: sum of 2 quarters · filed 2023-12-11
$42.00M
10-Q · filed 2023-12-11
$56.00M
derived: sum of 4 quarters · filed 2024-03-08
2022-06-30$14.00M
10-Q · filed 2023-08-09
$28.00M
10-Q · filed 2023-08-09
$42.00M
derived: sum of 3 quarters · filed 2024-03-08
$56.50M
derived: sum of 4 quarters · filed 2024-03-08
2022-03-31$14.00M
10-Q · filed 2023-05-10
$28.00M
derived: sum of 2 quarters · filed 2024-03-08
$42.50M
derived: sum of 3 quarters · filed 2024-03-08
$57.60M
derived: sum of 4 quarters · filed 2024-03-08
2021-12-31$14.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08
$28.50M
derived: sum of 2 quarters · filed 2024-03-08
$43.60M
derived: sum of 3 quarters · filed 2024-03-08
$58.50M
10-K · filed 2024-03-08
2021-09-30$14.50M
10-Q · filed 2022-11-09
$29.60M
derived: sum of 2 quarters · filed 2022-11-09
$44.50M
10-Q · filed 2022-11-09
$59.50M
derived: sum of 4 quarters · filed 2023-12-11
2021-06-30$15.10M
10-Q · filed 2022-08-02
$30.00M
10-Q · filed 2022-08-02
$45.00M
derived: sum of 3 quarters · filed 2023-12-11
$60.00M
derived: sum of 4 quarters · filed 2023-12-11
2021-03-31$14.90M
10-Q · filed 2022-04-29
$29.90M
derived: sum of 2 quarters · filed 2023-12-11
$44.90M
derived: sum of 3 quarters · filed 2023-12-11
$59.90M
derived: sum of 4 quarters · filed 2023-12-11
2020-12-31$15.00M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11
$30.00M
derived: sum of 2 quarters · filed 2023-12-11
$45.00M
derived: sum of 3 quarters · filed 2023-12-11
$59.80M
10-K/A · filed 2023-12-11
2020-09-30$15.00M
10-Q · filed 2021-11-05
$30.00M
derived: sum of 2 quarters · filed 2021-11-05
$44.80M
10-Q · filed 2021-11-05
$59.60M
derived: sum of 4 quarters · filed 2022-02-25
2020-06-30$15.00M
10-Q · filed 2021-07-30
$29.80M
10-Q · filed 2021-07-30
$44.60M
derived: sum of 3 quarters · filed 2022-02-25
$59.30M
derived: sum of 4 quarters · filed 2022-02-25
2020-03-31$14.80M
10-Q · filed 2021-04-30
$29.60M
derived: sum of 2 quarters · filed 2022-02-25
$44.30M
derived: sum of 3 quarters · filed 2022-02-25
$59.00M
derived: sum of 4 quarters · filed 2022-02-25
2019-12-31$14.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25
$29.50M
derived: sum of 2 quarters · filed 2022-02-25
$44.20M
derived: sum of 3 quarters · filed 2022-02-25
$58.70M
10-K · filed 2022-02-25
2019-09-30$14.70M
10-Q · filed 2020-11-06
$29.40M
derived: sum of 2 quarters · filed 2020-11-06
$43.90M
10-Q · filed 2020-11-06
$57.20M
derived: sum of 4 quarters · filed 2021-02-19
2019-06-30$14.70M
10-Q · filed 2020-07-31
$29.20M
10-Q · filed 2020-07-31
$42.50M
derived: sum of 3 quarters · filed 2021-02-19
$46.40M
derived: sum of 4 quarters · filed 2021-02-19
2019-03-31$14.50M
10-Q · filed 2020-05-01
$27.80M
derived: sum of 2 quarters · filed 2021-02-19
$31.70M
derived: sum of 3 quarters · filed 2021-02-19
$35.60M
derived: sum of 4 quarters · filed 2021-02-19
2018-12-31$13.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19
$17.20M
derived: sum of 2 quarters · filed 2021-02-19
$21.10M
derived: sum of 3 quarters · filed 2021-02-19
$25.00M
10-K · filed 2021-02-19
2018-09-30$3.90M
10-Q · filed 2019-11-07
$7.80M
derived: sum of 2 quarters · filed 2019-11-07
$11.70M
10-Q · filed 2019-11-07
$15.60M
derived: sum of 4 quarters · filed 2020-02-25
2018-06-30$3.90M
10-Q · filed 2019-08-02
$7.80M
10-Q · filed 2019-08-02
$11.70M
derived: sum of 3 quarters · filed 2020-02-25
$13.30M
derived: sum of 4 quarters · filed 2020-02-25
2018-03-31$3.90M
10-Q · filed 2019-05-08
$3.91M
10-Q · filed 2018-05-04
$7.80M
derived: sum of 2 quarters · filed 2020-02-25
$9.40M
derived: sum of 3 quarters · filed 2020-02-25
$11.00M
derived: sum of 4 quarters · filed 2020-02-25
2017-12-31$3.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
$5.50M
derived: sum of 2 quarters · filed 2020-02-25
$7.10M
derived: sum of 3 quarters · filed 2020-02-25
$8.60M
10-K · filed 2020-02-25
$8.57M
10-K · filed 2018-02-23
2017-09-30$1.60M
10-Q · filed 2018-11-02
$1.55M
10-Q · filed 2017-11-03
$3.20M
derived: sum of 2 quarters · filed 2018-11-02
$4.70M
10-Q · filed 2018-11-02
$4.66M
10-Q · filed 2017-11-03
$6.42M
derived: sum of 4 quarters · filed 2019-02-22
2017-06-30$1.60M
10-Q · filed 2018-08-03
$1.55M
10-Q · filed 2017-08-04
$3.10M
10-Q · filed 2018-08-03
$3.11M
10-Q · filed 2017-08-04
$4.82M
derived: sum of 3 quarters · filed 2019-02-22
$6.47M
derived: sum of 4 quarters · filed 2019-02-22
2017-03-31$1.55M
10-Q · filed 2018-05-04
$3.22M
derived: sum of 2 quarters · filed 2019-02-22
$4.87M
derived: sum of 3 quarters · filed 2019-02-22
$6.71M
derived: sum of 4 quarters · filed 2019-02-22
2016-12-31$1.66M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22
$3.31M
derived: sum of 2 quarters · filed 2019-02-22
$5.16M
derived: sum of 3 quarters · filed 2019-02-22
$7.00M
10-K · filed 2019-02-22
$6.89M
10-K · filed 2017-02-28
2016-09-30$1.65M
10-Q · filed 2017-11-03
$3.49M
derived: sum of 2 quarters · filed 2017-11-03
$5.34M
10-Q · filed 2017-11-03
$7.18M
derived: sum of 4 quarters · filed 2018-02-23
2016-06-30$1.84M
10-Q · filed 2017-08-04
$2.37M
10-Q · filed 2016-08-05
$3.69M
10-Q · filed 2017-08-04
$4.73M
10-Q · filed 2016-08-05
$5.53M
derived: sum of 3 quarters · filed 2018-02-23
$7.37M
derived: sum of 4 quarters · filed 2018-02-23
2016-03-31$1.84M
10-Q · filed 2017-05-05
$2.36M
10-Q · filed 2016-05-06
$3.69M
derived: sum of 2 quarters · filed 2018-02-23
$5.53M
derived: sum of 3 quarters · filed 2018-02-23
$7.92M
derived: sum of 4 quarters · filed 2018-02-23
2015-12-31$1.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
$3.69M
derived: sum of 2 quarters · filed 2018-02-23
$6.08M
derived: sum of 3 quarters · filed 2018-02-23
$7.38M
10-K · filed 2018-02-23
$9.27M
10-K · filed 2016-02-29
2015-09-30$1.84M
10-Q · filed 2016-11-09
$2.37M
10-Q · filed 2015-11-06
$4.24M
derived: sum of 2 quarters · filed 2016-11-09
$5.53M
10-Q · filed 2016-11-09
$6.91M
10-Q · filed 2015-11-06
$7.29M
derived: sum of 4 quarters · filed 2017-02-28
2015-06-30$2.39M
10-Q · filed 2016-08-05
$4.53M
10-Q · filed 2016-08-05
$5.44M
derived: sum of 3 quarters · filed 2017-02-28
$7.66M
derived: sum of 4 quarters · filed 2017-02-28
2015-03-31$2.14M
10-Q · filed 2016-05-06
-$2.14M
10-Q · filed 2015-05-08
$3.05M
derived: sum of 2 quarters · filed 2017-02-28
$5.26M
derived: sum of 3 quarters · filed 2017-02-28
$7.51M
derived: sum of 4 quarters · filed 2017-02-28
2014-12-31$907.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
$3.12M
derived: sum of 2 quarters · filed 2017-02-28
$5.37M
derived: sum of 3 quarters · filed 2017-02-28
$6.99M
10-K · filed 2017-02-28
-$8.00M
10-K · filed 2015-03-09
2014-09-30$2.21M
10-Q · filed 2015-11-06
-$6.08M
10-Q · filed 2014-11-10
$4.46M
derived: sum of 2 quarters · filed 2015-11-06
$6.08M
10-Q · filed 2015-11-06
2014-06-30$2.25M
10-Q · filed 2015-08-06
-$3.87M
10-Q · filed 2014-08-08
$3.87M
10-Q · filed 2015-08-06
2014-03-31-$1.64M
10-Q · filed 2015-05-08
-$1.62M
10-Q · filed 2014-05-12
2013-12-31$1.95M
10-K · filed 2016-02-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
ENANTA PHARMACEUTICALS INC (ENTA)United States$0.349B-6.72
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Rezolute, Inc. (RZLT)United States$0.382B-6.45